NCT00578682View on ClinicalTrials.gov

A Phase I, Randomized, Double-Blind, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

October 31, 2010

Study Completion Date

November 30, 2010

Conditions
Healthy
Interventions
BIOLOGICAL

MEDI-557

Single IV dose of 3 mg/kg

BIOLOGICAL

MEDI-557

Single IV dose of 15 mg/kg

BIOLOGICAL

MEDI-557

Single IV dose of 30 mg/kg

BIOLOGICAL

MEDI-557

Single IV dose of 0.3 mg/kg

Trial Locations (1)

32117

Covance Daytona Beach, Daytona Beach

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT00578682 - A Phase I, Randomized, Double-Blind, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557 | Biotech Hunter | Biotech Hunter